Recovery research fieldbook Evidence, not treatment advice
Recovery archive

Published recovery field note

Effect of recombinant human growth hormone on rotator cuff ... - PubMed

Randomized Controlled Trial . 2018 May;27(5):777-785. doi: 10.1016/j.jse.2017.11.019. Epub 2018 Jan 11. Affiliations PMID: 29337026 DOI: 10.1016/j.jse.2017.11.019 Randomized Controlled Trial Effect of recombinant human growth hormone on rotator cuff healing after arthroscopic repair: preliminary result of a multicenter, prospective, randomized, open-label blinded end point clinical exploratory trial Joo Han Oh et al. J Shoulder Elbow Surg. 2018 May. Abstract Background: This study evaluated the effect of systemic injection of recombinant human growth hormone (rhGH) on outcomes after arthroscopic rotator cuff repair. Methods: This multicenter, prospective, randomized, comparative trial, randomized patients who underwent arthroscopic repair of large-sized rotator cuff tears into 3 groups: rhGH 4 mg group (n = 26), rhGH 8 mg group (n = 24) , and control group (n = 26). Sustained release rhGH was injected subcutaneously once weekly for 3 months postoperatively. The healing failure rate (pr

Context first

Study findings do not automatically establish clinical benefit, safety, dosing, or suitability for an individual.

Randomized Controlled Trial

. 2018 May;27(5):777-785.

doi: 10.1016/j.jse.2017.11.019. Epub 2018 Jan 11.

Affiliations

PMID: 29337026 DOI: 10.1016/j.jse.2017.11.019

Randomized Controlled Trial

Effect of recombinant human growth hormone on rotator cuff healing after arthroscopic repair: preliminary result of a multicenter, prospective, randomized, open-label blinded end point clinical exploratory trial

Joo Han Oh et al. J Shoulder Elbow Surg. 2018 May.

Abstract

Background: This study evaluated the effect of systemic injection of recombinant human growth hormone (rhGH) on outcomes after arthroscopic rotator cuff repair.

Methods: This multicenter, prospective, randomized, comparative trial, randomized patients who underwent arthroscopic repair of large-sized rotator cuff tears into 3 groups: rhGH 4 mg group (n = 26), rhGH 8 mg group (n = 24) , and control group (n = 26). Sustained release rhGH was injected subcutaneously once weekly for 3 months postoperatively. The healing failure rate (primary end point), fatty infiltration, and atrophy of the supraspinatus muscle, and functional scores (Constant and American Shoulder and Elbow Surgeons scores) were evaluated at 6 months. Range of motion, pain visual analog scale, and serum insulin-like growth factor-1 level were measured at each follow-up.

Results: The healing failure rate was similar between groups (rhGH 4 mg group, 30.8%; rhGH 8 mg group, 16.7%; and control group, 34.6%; all P > .05) The proportion of severe fatty infiltration (Goutallier grade ≥3) was 20.8% in the rhGH 8 mg group, 23.1% in the rhGH 4 mg group, and 34.6% in the control group (P > .05). Functional outcomes, range of motion, and pain visual analog scale were similar between groups (all P > .05). The rhGH 8 mg group showed more increased peak insulin-like growth factor-1 level (279.43 ng/mL) than the rhGH 4 mg group ((196.82 ng/mL) and control group (186.31 ng/mL), which was not statistically different (all P > .05). No rhGH injection-related major safety issues occurred.

Conclusions: This preliminary study showed no statistically significant improvement in healing or outcomes related to the treatment of rhGH after rotator cuff repair. However, further study with more enrolled patients after resetting the rhGH dose or daily administration protocol would be mandatory.

Keywords: Recombinant human growth hormone; atrophy; fatty infiltration; healing failure; insulin-like growth factor-1; rotator cuff, healing.

Copyright © 2017 Journal of Shoulder and Elbow Surgery Board of Trustees. Published by Elsevier Inc. All rights reserved.

PubMed Disclaimer

Connected topics

Follow this recovery question